

Timothy B Niewold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8872035/publications.pdf>

Version: 2024-02-01

190
papers

11,323
citations

20817

60
h-index

34986

98
g-index

202
all docs

202
docs citations

202
times ranked

11878
citing authors

#	ARTICLE	IF	CITATIONS
1	Axonal dysfunction is associated with interferon- β levels in childhood-onset systemic lupus erythematosus: a multivoxel magnetic resonance spectroscopy study. <i>Rheumatology</i> , 2022, 61, 1529-1537.	1.9	2
2	Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. <i>Translational Research</i> , 2022, 244, 47-55.	5.0	9
3	Type I Interferons in Autoimmunity. <i>Journal of Investigative Dermatology</i> , 2022, 142, 793-803.	0.7	21
4	Artificial intelligence and deep learning to map immune cell types in inflamed human tissue. <i>Journal of Immunological Methods</i> , 2022, 505, 113233.	1.4	4
5	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. <i>Journal of Rheumatology</i> , 2022, 49, 388-397.	2.0	11
6	Is Rheumatoid Arthritis a Causal Factor in Cardiovascular Disease?. <i>Arthritis and Rheumatology</i> , 2022, 74, 1612-1614.	5.6	1
7	The role of interferons in systemic lupus erythematosus. , 2021, , 171-178.		0
8	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , 2021, 232, 13-36.	5.0	69
9	Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies. <i>Rheumatology International</i> , 2021, 41, 219-225.	3.0	4
10	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	3.5	12
11	Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. <i>Journal of Autoimmunity</i> , 2021, 119, 102615.	6.5	37
12	T Cells in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 379-393.	1.9	7
13	Single-cell expression quantitative trait loci (eQTL) analysis of SLE-risk loci in lupus patient monocytes. <i>Arthritis Research and Therapy</i> , 2021, 23, 290.	3.5	8
14	Novel genetic associations with interferon in systemic lupus erythematosus identified by replication and fine-mapping of trait-stratified genome-wide screen. <i>Cytokine</i> , 2020, 132, 154631.	3.2	19
15	Familial Aggregation of Childhood and Adulthood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1147-1151.	3.4	14
16	A Successful Trial for Lupus – How Good Is Good Enough?. <i>New England Journal of Medicine</i> , 2020, 382, 287-288.	27.0	15
17	Type I interferon in the pathogenesis of systemic lupus erythematosus. <i>Current Opinion in Immunology</i> , 2020, 67, 87-94.	5.5	104
18	Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 1384.	4.8	12

#	ARTICLE	IF	CITATIONS
19	Type I interferon antagonists in clinical development for lupus. Expert Opinion on Investigational Drugs, 2020, 29, 1025-1041.	4.1	14
20	Lessons from precision medicine in rheumatology. Multiple Sclerosis Journal, 2020, 26, 533-539.	3.0	11
21	Type I interferon. Cytokine, 2020, 132, 155109.	3.2	1
22	TLR7 and TLR8 Differentially Activate the IRF and NF- κ B Pathways in Specific Cell Types to Promote Inflammation. ImmunoHorizons, 2020, 4, 93-107.	1.8	72
23	Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus. ACR Open Rheumatology, 2019, 1, 499-506.	2.1	10
24	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Research and Therapy, 2019, 21, 107.	3.5	129
25	When pregnancy tames the wolf. Journal of Experimental Medicine, 2019, 216, 1012-1013.	8.5	1
26	Cytokines in Lupus. , 2019, , 137-152.		2
27	Manifestations of systemic lupus erythematosus in female patients with polysomy X: Possible roles of chromosome X. Modern Rheumatology, 2019, 29, 192-194.	1.8	4
28	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
29	Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds. Lupus Science and Medicine, 2018, 5, e000246.	2.7	12
30	Type I interferon in rheumatic diseases. Nature Reviews Rheumatology, 2018, 14, 214-228.	8.0	226
31	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity, 2018, 49, 725-739.e6.	14.3	661
32	The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene, 2018, 668, 59-72.	2.2	94
33	Pathogenic Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1933-1945.	5.6	68
34	Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. Clinical Rheumatology, 2018, 37, 1011-1015.	2.2	5
35	Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy. Pharmaceutical Medicine, 2017, 31, 81-88.	1.9	10
36	Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 153-158.	0.9	40

#	ARTICLE	IF	CITATIONS
37	Lupus-Associated Functional Polymorphism in <i>PNP</i> Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. <i>Arthritis and Rheumatology</i> , 2017, 69, 2328-2337.	5.6	24
38	Brief Report: A Novel <i>ELANE</i> Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection. <i>Arthritis and Rheumatology</i> , 2017, 69, 2396-2401.	5.6	17
39	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	12.8	314
40	By CyTOF. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1423-1424.	2.4	4
41	Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy. <i>Lupus Science and Medicine</i> , 2017, 4, e000202.	2.7	39
42	Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 117-124.	2.0	25
43	Genetics of human lupus nephritis. <i>Clinical Immunology</i> , 2017, 185, 32-39.	3.2	53
44	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017, 69, 630-642.	5.6	56
45	Differential Expression of <i>miR-4520a</i> Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). <i>Journal of Cellular Physiology</i> , 2017, 232, 1326-1336.	4.1	23
46	Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 747-757.	4.3	28
47	Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study. <i>Autoimmune Diseases</i> , 2017, 2017, 1-5.	0.6	7
48	CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2017, 127, 1271-1283.	8.2	100
49	Cytokines: Diagnostic and Clinical Applications. , 2016, , 357-364.		0
50	Dynamics of pulse wave velocity and vascular augmentation index in association with endothelial progenitor cells in SLE. <i>Lupus Science and Medicine</i> , 2016, 3, e000185.	2.7	4
51	Targeting type I interferon in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2016, 12, 377-378.	8.0	14
52	The Thr300Ala variant in <i>ATG16L1</i> is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. <i>Gut</i> , 2016, 65, 456-464.	12.1	71
53	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2007-2013.	0.9	16
54	Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients. <i>Gene</i> , 2016, 583, 90-101.	2.2	35

#	ARTICLE	IF	CITATIONS
55	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2014-2021.	0.9	200
56	Drugs in early clinical development for Systemic Lupus Erythematosus. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 573-583.	4.1	10
57	Increased pretreatment serum IFN- γ /IFN- β ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.9	59
58	The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. <i>Gene</i> , 2016, 576, 14-21.	2.2	106
59	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 242-252.	0.9	10
60	Advances in lupus genetics. <i>Current Opinion in Rheumatology</i> , 2015, 27, 440-447.	4.3	44
61	Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015, 16, 2019-2034.	1.3	49
62	Interferon regulatory factors: critical mediators of human lupus. <i>Translational Research</i> , 2015, 165, 283-295.	5.0	33
63	Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. <i>Journal of Autoimmunity</i> , 2015, 60, 51-58.	6.5	71
64	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015, 161, 157-162.	3.2	10
65	Immunological Biomarkers in Dermatomyositis. <i>Current Rheumatology Reports</i> , 2015, 17, 68.	4.7	13
66	Immunogenetics of systemic lupus erythematosus: A comprehensive review. <i>Journal of Autoimmunity</i> , 2015, 64, 125-136.	6.5	182
67	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	2.9	74
68	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. <i>PLoS ONE</i> , 2015, 10, e0117614.	2.5	4
69	Sirukumab: a novel therapy for lupus nephritis?. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1449-1455.	4.1	18
70	Dysregulation of antiviral helicase pathways in systemic lupus erythematosus. <i>Frontiers in Genetics</i> , 2014, 5, 418.	2.3	22
71	Type I Interferon in Human Autoimmunity. <i>Frontiers in Immunology</i> , 2014, 5, 306.	4.8	25
72	Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. <i>Lupus</i> , 2014, 23, 881-888.	1.6	24

#	ARTICLE	IF	CITATIONS
73	End-stage Renal Disease in African Americans With Lupus Nephritis Is Associated With <i>APOL1</i> . <i>Arthritis and Rheumatology</i> , 2014, 66, 390-396.	5.6	242
74	Autoimmune Disease Genetics 2013. <i>Journal of Immunology Research</i> , 2014, 2014, 1-2.	2.2	2
75	Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription. <i>American Journal of Human Genetics</i> , 2014, 94, 586-598.	6.2	59
76	Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM. <i>Human Molecular Genetics</i> , 2014, 23, 4161-4176.	2.9	25
77	Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 46-54.	0.2	55
78	Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, R18.	3.5	32
79	Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. <i>Cytokine</i> , 2013, 61, 906-911.	3.2	28
80	Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. <i>Journal of Rheumatology</i> , 2013, 40, 842-849.	2.0	15
81	Genetics of the type I interferon pathway in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 657-669.	0.3	49
82	Brief Report: Interferon- α Induction and Detection of Anti-RO, Anti-La, Anti-Sm, and Anti-RNP Autoantibodies by Autoantigen Microarray Analysis in Juvenile Dermatomyositis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2424-2429.	6.7	37
83	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. <i>Frontiers in Immunology</i> , 2013, 4, 238.	4.8	17
84	Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression. <i>PLoS Genetics</i> , 2013, 9, e1003870.	3.5	36
85	Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production. <i>PLoS Genetics</i> , 2013, 9, e1003222.	3.5	107
86	Trans-Ancestral Studies Fine Map the SLE-Susceptibility Locus TNFSF4. <i>PLoS Genetics</i> , 2013, 9, e1003554.	3.5	50
87	MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2013, 9, e1003336.	3.5	107
88	Fine mapping of Xq28: both <i>MECP2</i> and <i>IRAK1</i> contribute to risk for systemic lupus erythematosus in multiple ancestral groups. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 437-444.	0.9	97
89	ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1743-1754.	6.1	70
90	Functional genetic polymorphisms in <i>ILT3</i> are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 596-601.	0.9	28

#	ARTICLE	IF	CITATIONS
91	Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients. <i>Frontiers in Immunology</i> , 2013, 4, 309.	4.8	50
92	Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2013, 4, 319.	4.8	81
93	Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. <i>Lupus</i> , 2013, 22, 1523-1525.	1.6	15
94	Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. <i>Genes and Immunity</i> , 2013, 14, 471-478.	4.1	54
95	Cytokines and Interferons in Lupus. , 2013, , 62-75.		1
96	Familial Aggregation of High Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	12
97	PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes. <i>PLoS ONE</i> , 2013, 8, e69404.	2.5	57
98	The Autoimmune Disease Risk Allele of UBE2L3 in African American Patients with Systemic Lupus Erythematosus: A Recessive Effect Upon Subphenotypes. <i>Journal of Rheumatology</i> , 2012, 39, 73-78.	2.0	25
99	Autoimmune Disease Genetics. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	1
100	Gene-Expression-Guided Selection of Candidate Loci and Molecular Phenotype Analyses Enhance Genetic Discovery in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	12
101	Analysis of autosomal genes reveals geneâ€sex interactions and higher total genetic risk in men with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 694-699.	0.9	87
102	Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. <i>Genes and Immunity</i> , 2012, 13, 232-238.	4.1	58
103	A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. <i>Genes and Immunity</i> , 2012, 13, 380-387.	4.1	50
104	Genetic Ancestry, Serum Interferon-Î± Activity, and Autoantibodies in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1238-1240.	2.0	29
105	IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 463-469.	0.9	127
106	Cytokines in Systemic Lupus Erythematosus 2011. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-1.	3.0	3
107	Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	38
108	Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indianâ€European populations. <i>Arthritis and Rheumatism</i> , 2012, 64, 3687-3694.	6.7	70

#	ARTICLE	IF	CITATIONS
109	Association of two independent functional risk haplotypes in <i>TNIP1</i> with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3695-3705.	6.7	69
110	The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. <i>Translational Research</i> , 2012, 160, 321-331.	5.0	45
111	Variation in the <i>ICAM1</i> – <i>ICAM4</i> – <i>ICAM5</i> locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1809-1814.	0.9	60
112	Brief Report: Large-scale analysis of tumor necrosis factor β levels in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2947-2952.	6.7	76
113	Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3383-3387.	6.7	36
114	Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins. <i>Archives of Neurology</i> , 2012, 69, 1303.	4.5	47
115	Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 313, 48-53.	0.6	64
116	Evaluation of <i>TRAF6</i> in a large multiethnic lupus cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 1960-1969.	6.7	51
117	Identification of IRF8, TMEM39A, and IKZF3-ZBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study. <i>American Journal of Human Genetics</i> , 2012, 90, 648-660.	6.2	161
118	Evidence for gene–gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 485-492.	6.7	53
119	How Do You Handle Your Antibodies?. <i>Science Translational Medicine</i> , 2012, 4, .	12.4	0
120	Allergic to the Cold. <i>Science Translational Medicine</i> , 2012, 4, .	12.4	0
121	Interferon Alpha as a Primary Pathogenic Factor in Human Lupus. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 887-892.	1.2	134
122	Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1569-1574.	0.9	185
123	Interferon regulatory factors in human lupus pathogenesis. <i>Translational Research</i> , 2011, 157, 326-331.	5.0	88
124	Linkage of Type I Interferon Activity and TNF-Alpha Levels in Serum with Sarcoidosis Manifestations and Ancestry. <i>PLoS ONE</i> , 2011, 6, e29126.	2.5	25
125	Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. <i>Nature Genetics</i> , 2011, 43, 253-258.	21.4	242
126	Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. <i>Genes and Immunity</i> , 2011, 12, 270-279.	4.1	226

#	ARTICLE	IF	CITATIONS
127	Identification of a Systemic Lupus Erythematosus Susceptibility Locus at 11p13 between PDHX and CD44 in a Multiethnic Study. American Journal of Human Genetics, 2011, 88, 83-91.	6.2	72
128	The Unexplained Female Predominance of Systemic Lupus Erythematosus: Clues from Genetic and Cytokine Studies. Clinical Reviews in Allergy and Immunology, 2011, 40, 42-49.	6.5	199
129	Bone Health Issues in Sarcoidosis. Current Rheumatology Reports, 2011, 13, 265-272.	4.7	52
130	A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Molecular Medicine, 2011, 3, 142-152.	6.9	91
131	Network analysis of associations between serum interferon- α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis and Rheumatism, 2011, 63, 1044-1053.	6.7	222
132	Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis and Rheumatism, 2011, 63, 2396-2406.	6.7	63
133	Association of <i>PPP2CA</i> polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis and Rheumatism, 2011, 63, 2755-2763.	6.7	36
134	Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis and Rheumatism, 2011, 63, 3493-3501.	6.7	109
135	B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis and Rheumatism, 2011, 63, 3931-3941.	6.7	59
136	Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete. Lupus, 2011, 20, 501-506.	1.6	41
137	Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis. Pediatrics, 2011, 127, e1239-e1246.	2.1	74
138	Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN- α and Serologic Autoimmunity in Lupus Patients. Journal of Immunology, 2011, 187, 1298-1303.	0.8	143
139	Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 1752-1757.	0.9	110
140	Osteopontin Alleles Are Associated with Clinical Characteristics in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-6.	3.0	33
141	Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility. PLoS Genetics, 2011, 7, e1002079.	3.5	181
142	Stabilizing the Kidney's Skeleton. Science Translational Medicine, 2011, 3, .	12.4	1
143	Genetic Tug of War in the Immune System. Science Translational Medicine, 2011, 3, .	12.4	0
144	Actionable Pharmacogenetics for Epilepsy. Science Translational Medicine, 2011, 3, .	12.4	0

#	ARTICLE	IF	CITATIONS
145	Decoding Melanoma. Science Translational Medicine, 2011, 3, .	12.4	0
146	Inheriting Disease Severity. Science Translational Medicine, 2011, 03, .	12.4	0
147	Channeling Cognitive Performance. Science Translational Medicine, 2011, 3, .	12.4	0
148	Thinking Globally About Asthma. Science Translational Medicine, 2011, 3, .	12.4	0
149	One Size Doesn't Fit All. Science Translational Medicine, 2011, 3, .	12.4	0
150	It's What You Do that Matters. Science Translational Medicine, 2011, 3, .	12.4	0
151	Lenalidomide for the Treatment of Cryoglobulinemia and Undifferentiated Spondyloarthritis in a Patient With Multiple Myeloma. Journal of Clinical Rheumatology, 2010, 16, 90-91.	0.9	9
152	Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab. American Journal of Kidney Diseases, 2010, 56, e17-e21.	1.9	42
153	Gene-Gene-Sex Interaction in Cytokine Gene Polymorphisms Revealed by Serum Interferon Alpha Phenotype in Juvenile Dermatomyositis. Journal of Pediatrics, 2010, 157, 653-657.	1.8	33
154	Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon- α activity in lupus patients. Arthritis and Rheumatism, 2010, 62, 553-561.	6.7	139
155	Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis and Rheumatism, 2010, 62, 2813-2822.	6.7	60
156	Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Therapeutics and Clinical Risk Management, 2010, 6, 143.	2.0	26
157	TNF Inhibition As Novel Therapy For Refractory Sarcoidosis: Long Term Follow Up. , 2010, , .		1
158	52-Week Trial Results Of Adalimumab As Novel Therapy For Refractory, Progressive Pulmonary Sarcoidosis. , 2010, , .		1
159	Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations. PLoS ONE, 2010, 5, e9088.	2.5	105
160	Promoter Variant of <i>PIK3C3</i> Is Associated with Autoimmunity against Ro and Sm Epitopes in African-American Lupus Patients. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	25
161	Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	2
162	African-Derived Genetic Polymorphisms in <i>TNFAIP3</i> Mediate Risk for Autoimmunity. Journal of Immunology, 2010, 184, 7001-7009.	0.8	93

#	ARTICLE	IF	CITATIONS
163	The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-11.	3.0	44
164	Interferon Alpha in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	91
165	Rheumatologic Manifestations of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 463-473.	2.1	80
166	Genetic regulation of serum cytokines in systemic lupus erythematosus. Translational Research, 2010, 155, 109-117.	5.0	60
167	Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Research and Therapy, 2010, 12, R151.	3.5	103
168	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. Blood, 2010, 116, 3694-3694.	1.4	0
169	Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN- γ in Lupus Patients In Vivo. Journal of Immunology, 2009, 182, 34-38.	0.8	210
170	Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opinion on Biological Therapy, 2009, 9, 889-895.	3.1	58
171	Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Annals of the Rheumatic Diseases, 2009, 68, 1022-1029.	0.9	27
172	Elevated serum interferon- γ activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis and Rheumatism, 2009, 60, 1815-1824.	6.7	119
173	Age- and gender-specific modulation of serum osteopontin and interferon- γ by osteopontin genotype in systemic lupus erythematosus. Genes and Immunity, 2009, 10, 487-494.	4.1	92
174	Clinical Characteristics of Patients With Anti-Jo-1 Antibodies. Journal of Clinical Rheumatology, 2009, 15, 254-255.	0.9	45
175	Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-“positive mothers of children with neonatal lupus. Arthritis and Rheumatism, 2008, 58, 541-546.	6.7	84
176	Association of the IRF5 risk haplotype with high serum interferon- γ activity in systemic lupus erythematosus patients. Arthritis and Rheumatism, 2008, 58, 2481-2487.	6.7	246
177	Age- and sex-related patterns of serum interferon- γ activity in lupus families. Arthritis and Rheumatism, 2008, 58, 2113-2119.	6.7	74
178	The <i>PTPN22</i> C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon- γ activity and low tumor necrosis factor γ levels in patients with lupus. Arthritis and Rheumatism, 2008, 58, 2818-2823.	6.7	82
179	Interferon Alpha-Induced Lupus. Journal of Clinical Rheumatology, 2008, 14, 131-132.	0.9	52
180	Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 193-201.	0.5	132

#	ARTICLE	IF	CITATIONS
181	Augmented interferon- γ pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis and Rheumatism, 2007, 56, 3995-4004.	6.7	140
182	High serum IFN- γ activity is a heritable risk factor for systemic lupus erythematosus. Genes and Immunity, 2007, 8, 492-502.	4.1	390
183	Concomitant interferon- γ therapy and tumor necrosis factor α inhibition for rheumatoid arthritis and hepatitis C. Arthritis and Rheumatism, 2006, 54, 2335-2337.	6.7	23
184	Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange. American Journal of Hematology, 2006, 81, 454-457.	4.1	9
185	Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clinical Rheumatology, 2005, 24, 178-181.	2.2	159
186	59-Year-Old Woman With Progressive Dyspnea on Exertion. Mayo Clinic Proceedings, 2004, 79, 1567-1570.	3.0	1
187	Post-streptococcal reactive arthritis and glomerulonephritis in an adult. Clinical Rheumatology, 2003, 22, 350-352.	2.2	10
188	78-Year-Old Woman With Fever, Weight Loss, and Rash. Mayo Clinic Proceedings, 2003, 78, 635-638.	3.0	2
189	27-Year-Old Woman With Numbness and Weakness of the Extremities. Mayo Clinic Proceedings, 2003, 78, 95-98.	3.0	2
190	CheB is required for behavioural responses to negative stimuli during chemotaxis in Bacillus subtilis. Molecular Microbiology, 2000, 35, 44-57.	2.5	50